- Conditions
- Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
- Interventions
- Alpha-1 MP
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 20 Years to 72 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 93
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- COVID-19
- Interventions
- Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
- Biological · Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
- Conditions
- Pancreatitis, Chronic; Diabetes; Transplant
- Interventions
- etanercept, Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
- Interventions
- Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 1,675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- No Intervention
- Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Charleston, South Carolina • Nashville, Tennessee
- Conditions
- Kidney Transplant, Type 1 Diabetes
- Interventions
- Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin, Basiliximab, Etanercept
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Sonoelastography, Elastography, Elastograms, Liver Fibrosis, Hepatic Fibrosis, Cirrhosis, Pediatrics
- Interventions
- Shear wave sonoelastography
- Device
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- rAAV1-CB-hAAT
- Drug
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Worcester, Massachusetts • Cincinnati, Ohio
- Conditions
- Covid19, Pneumonia, Viral
- Interventions
- alpha1-proteinase inhibitor, Antiviral Agents
- Drug
- Lead sponsor
- Blessing Corporate Services, Inc
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Hannibal, Missouri
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- alpha-1 proteinase inhibitor (human)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- rAAV2-CB-hAAT Gene Vector
- Genetic
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Worcester, Massachusetts
- Conditions
- Alpha-1 Antitrypsin Deficiency, AATD
- Interventions
- INBRX-101/rhAAT-Fc
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
- Interventions
- History and physical exam., Blood draw., Pulmonary function testing., Albuterol inhaler.
- Procedure · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2033
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
- Conditions
- Alpha-1 Antitrypsin Deficiency (AATD)
- Interventions
- TSRA-196
- Drug
- Lead sponsor
- Tessera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Belcesiran, Placebo
- Drug · Other
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- La Jolla, California • Gainesville, Florida • Charleston, South Carolina
- Conditions
- Alpha 1-Antitrypsin, COPD, Antibody Deficiency
- Interventions
- 20-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Graft-versus-host-disease, GVHD
- Interventions
- Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- John Levine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Emphysema
- Interventions
- Spiration Valve System, Medical Management
- Device · Other
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 32
- States / cities
- Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema
- Interventions
- SAR447537, Zemaira
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- rAAV1-CB-hAAT
- Biological
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Worcester, Massachusetts